WO2026062542 - METHYLPHENIDATE MODIFIED RELEASE FORMULATIONS
National phase entry is expected:
Publication Number
WO/2026/062542
Publication Date
26.03.2026
International Application No.
PCT/IB2025/059357
International Filing Date
18.09.2025
Title **
[English]
METHYLPHENIDATE MODIFIED RELEASE FORMULATIONS
[French]
FORMULATIONS À LIBÉRATION MODIFIÉE DE MÉTHYLPHÉNIDATE
Applicants **
GRANULES PHARMACEUTICALS INC.
Inventors
GORUKANTI, Sudhir Rao
BHATTARAI, Rajan Sharma
VASIREDDY, Mallikharjun
DESAI, Chintan
Priority Data
63/696,458
19.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP Australia
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1958 | |
| EPO | Filing, Examination, Granting | 11670 | |
| Japan | Filing, Examination, Granting | 1907 | |
| South Korea | Filing, Examination, Granting | 1603 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,878
Contact Us
Abstract[English]
The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.[French]
La présente invention concerne des compositions thérapeutiques et des méthodes pour le traitement d'un trouble du déficit de l'attention (TDA), ou d'un trouble du déficit de l'attention/hyperactivité (TDAH). La présente invention concerne plus particulièrement une formulation pharmaceutique à libération modifiée conçue pour améliorer l'administration et l'efficacité de stimulants du système nerveux central (SNC). La composition est constituée d'un noyau contenant un médicament avec un stimulant du SNC et d'excipients pharmaceutiquement acceptables. Ce noyau est enrobé d'une couche à libération prolongée (SR) comprenant un ou plusieurs polymères choisis parmi des polymères insolubles dans l'eau et des polymères pH-dépendants insolubles dans l'eau et un ou plusieurs excipients pharmaceutiquement acceptables qui régulent la libération progressive du médicament. Autour de la couche SR, une couche externe à libération retardée (DR) régule le début d'une libération de médicament. Cette approche vise à améliorer le soulagement des symptômes, à réduire la fréquence des prises et à améliorer l'observance du patient dans le traitement du TDA et du TDAH.